)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ODI Pharma
ODI Pharma (ODI) investor relations material
ODI Pharma Q4 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 25/26 earnings summary27 Aug, 2026
Executive summary
Achieved significant progress in commercial positioning, volume growth, and profitability, especially in Poland, with net sales rising to SEK 32.9 million from SEK 3.1 million year-over-year and profit after financial items improving to SEK 2.0 million from a loss of SEK 5.9 million.
Four consecutive quarters of positive EBITDA and three consecutive quarters of positive net income signal sustained operational improvement.
Ended the year debt-free after repaying the remaining EUR 150,000 working capital loan, strengthening the balance sheet.
Added a new commission-based contract in Switzerland, contributing positively to net income.
Financial highlights
Full-year net sales: SEK 32,915,945 (up from SEK 3,133,879 year-over-year).
Profit after financial items: SEK 1,987,683 (compared to a loss of SEK 5,929,115 year-over-year).
Q4 net sales: SEK 3,197,373 (up from SEK 6,461 in Q4 last year, but down sequentially from Q3 due to order timing).
Q4 profit after financial items: SEK 153,040 (compared to a loss of SEK 1,660,970 in Q4 last year).
Result per share for the year: SEK 0.11 (up from SEK -0.35 year-over-year).
Outlook and guidance
Focus remains on consolidating and strengthening the position in Poland, with continued monitoring of regulatory and commercial developments in other European markets such as France.
European medical cannabis market expected to grow in volume, though pricing pressure and regulatory changes will remain key factors.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ODI Pharma
- Record sales and profitability highlight strong growth and stability in the European cannabis market.ODI
Q3 25/26 - Q2 revenue soared 84% sequentially, returning to profit and strengthening financial stability.ODIQ2 25/26
- Q1 net sales soared and losses narrowed, reflecting improved stability and growth in Poland.ODIQ1 25/26
- Revenue fell and losses deepened, but financial position was strengthened for future growth.ODIQ4 24/25
- Q1 loss and revenue decline offset by optimism from Poland's increased cannabis import quota.ODIQ1 24/25
- ODI Pharma posted robust revenue growth and profitability, focusing on European medical cannabis.ODIQ4 23/24
- Sales fell and losses widened, but import issues resolved and profitability expected to return.ODIQ3 24/25
- ODI Pharma faces losses but secures funding and grows its Polish medical cannabis market share.ODIQ2 24/25
Next ODI Pharma earnings date
Q1 26/2726 Nov, 2026
ODI Pharma
Next ODI Pharma earnings date
Q1 26/2726 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ODI Pharma AB is a Sweden-based company operating in the pharmaceutical and healthcare sector. The company focuses on the production, distribution, and sale of medical cannabis products. It collaborates with licensed producers and healthcare providers to supply pharmaceutical-grade cannabis for therapeutic use. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Spotlight Stock Market.